MeetMe (MEET) PT Bumped to $4.25 at Roth Capital Post Q3

Roth Capital analyst Darren Aftahi reiterated a Buy rating and bumped his price target on MeetMe (NASDAQ: MEET) to $4.25 (from $4.00) following Q3 results.

Aftahi commented, "MEET shares continue to trade at distressed values, in our opinion, despite exceptionally strong 3Q results and an above consensus 4Q guide, even in light of higher marketing spend. Increased marketing should yield faster mobile user growth, which decelerated in 3Q, but still was a healthy ~19% y/y. On raised estimates, we bump our PT up from $4 to $4.25 and reiterate our Buy rating."

For an analyst ratings summary and ratings history on MeetMe click here. For more ratings news on MeetMe click here.

Shares of MeetMe closed at $2.41 yesterday.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• BMO Capital Starts Bicara Therapeutics Inc (BCAX) at Outperform
• BMO Capital Starts Aktis Oncology (AKTS) at Outperform